Burrill & Company identified more than $2.6bn in expected funding through nine healthcare initiatives announced since the end of February to end-March.
A host of new initiatives focused on funding translational research and early-stage companies brought together the public and private sector, particularly with the goal of building life sciences centers in specific locations. In all, Burrill & Company identified more than $2.6bn in expected funding through nine initiatives announced since the end of February to end-March.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
